Maplight Therapeutics (NASDAQ:MPLT) Releases Earnings Results, Misses Expectations By $1.42 EPS

Maplight Therapeutics (NASDAQ:MPLT) announced its quarterly earnings data on Thursday. The company reported ($2.47) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42), Zacks reports.

Maplight Therapeutics Stock Performance

NASDAQ MPLT opened at $18.55 on Friday. The business’s 50 day moving average price is $17.86. Maplight Therapeutics has a twelve month low of $12.24 and a twelve month high of $21.55. The stock has a market cap of $841.61 million and a PE ratio of -0.50.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MPLT. Wall Street Zen lowered Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Canaccord Genuity Group assumed coverage on Maplight Therapeutics in a research report on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Weiss Ratings initiated coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.80.

Insider Transactions at Maplight Therapeutics

In other Maplight Therapeutics news, Director Timothy John Garnett purchased 14,124 shares of the stock in a transaction dated Tuesday, February 10th. The shares were acquired at an average price of $17.89 per share, for a total transaction of $252,678.36. Following the completion of the acquisition, the director owned 14,124 shares of the company’s stock, valued at $252,678.36. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director George Pavlov purchased 9,920 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were acquired at an average cost of $17.86 per share, for a total transaction of $177,171.20. Following the completion of the transaction, the director directly owned 25,000 shares of the company’s stock, valued at $446,500. This trade represents a 65.78% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 39,124 shares of company stock valued at $693,846 and sold 74,612 shares valued at $1,368,065.

Hedge Funds Weigh In On Maplight Therapeutics

A number of large investors have recently made changes to their positions in the business. Siren L.L.C. acquired a new stake in shares of Maplight Therapeutics during the fourth quarter worth approximately $7,904,000. Perceptive Advisors LLC acquired a new position in Maplight Therapeutics in the 4th quarter valued at approximately $9,661,000. Pivotal bioVenture Partners Investment Advisor LLC purchased a new stake in Maplight Therapeutics in the 4th quarter worth approximately $10,743,000. T. Rowe Price Investment Management Inc. purchased a new stake in Maplight Therapeutics in the 4th quarter worth approximately $49,154,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Maplight Therapeutics during the 4th quarter valued at $34,026,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.